Scynexis Switches Focus To Hospital Indications For Ibrexafungerp
With sluggish sales so far for antifungal Brexafemme, approved for vulvovaginal candidiasis, Scynexis will look to out-license the product and cut staff.
With sluggish sales so far for antifungal Brexafemme, approved for vulvovaginal candidiasis, Scynexis will look to out-license the product and cut staff.